5KOHLMANN A, GROSSMANN V, NADARAJA- H N,et al. Next-generation sequencing-feasibility andpracticality in haematology[J]. Br J Haematol, 2013, 160..736-753.
6RAZA A,GALILI N. The genetic basis of phenotypic heterogeneity in myelodysplastic syndromes [J] Nat Rev Cancer, 2012,12 : 849- 859.
7WANG J,AI X,GALE R P,et al. TET2,ASXL1 and EZH2 mutations in Chinese with myelodysplastic syn- dromes[J]. Leuk Res, 2013,37 .. 305 - 311.
8CUI R, GALE R P,XU Z, et al. Clinical importance of SF3B1 mutations in Chinese with myelodysplastic syn- dromes with ring sideroblasts[J]. Leuk Res, 2012,36 : 1428-1433.
9SCHANZ J,TUCHLER H,SOLE F,et al. New com- prehensive cytogenetic scoring system for primary my- elodysplastic syndromes (MDS) and oligohlastic acute myeloid leukemia after MDS derived from an interna- tional database merge [J]. J Clin Oncol, 2012, 30..820-829.
10GREENBERG P L, TUECHLER H, SCHANZ J, et al. Revised international prognostic scoring system for myelodysplastic syndromes [J]. Blood, 2012, 120: 2454-2465.
3List AF. Myelodysplastic syndromes (MDS): an international practice and treatment survey. ASH Annual Meeting Abstracts,Atalanta, 2005:2534.
4Malcovati L, Germing U, Kuendgen A, et al. A WHO Classification-based prognostic scoring system (WPSS) for predicting survival in myelodysplastic syndromes. ASH Annual Meeting Abstracts, Atalanta, 2005:788.
5Deeg HJ. Transplant strategies for patients with myelodysplastic syndromes. Curt Opin Hematol, 2006, 13:61-66.
6Cutler CS, Lee SJ, Greenberg P, et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood, 2004, 104:579-585.
7List AF, Kurtin S, Roe DJ, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med, 2005,352:549-557.
8Kaminskas E, Farrell A, Abraham S, et al. Approval summary:azacitidine for treatment of myelodysplastic syndrome subtypes.Clin Cancer Res, 2005, 11:3604-3608.
9Wijermans PW, Lubbert M, Verhoef G, et al. An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2'-deoxycytidine (decitabine)in 177 patients. Ann Hematol, 2005, 84 Supple 13: 9-17.
10Kantarjian H, Issa JPJ, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes. Results of a phase Ⅲ randomized study. Cancer, 2006, 106 : 1794-1803.
